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Multiplex PCRAbstract Background: AmpC b-lactamases are often plasmid mediated that hydrolyze all
b-lactam antibiotics except cefepime and carbapenems.
Aim of the study: We aimed to evaluate the presence of AmpC b-lactamase among
Enterobacteriaceae isolates separated from patients with nosocomial infections, and to detect the
genetic basis for AmpC production in these strains.
Subjects and methods: 50 AmpC b-lactamase Enterobacteriaceae were analyzed for the presence
of AmpC production. Three phenotypic AmpC conﬁrmation assays (AmpC E test, the disk approx-
imation test, Amp C EDTA disc) were able to detect the majority of AmpC-positive strains cor-
rectly. Molecular detection of plasmid mediated AmpC by multiplex PCR was conducted on them.
Results: The results show that from the 148 total isolates obtained from ICU admitted patients
with suspected nosocomial infections, 50 (33.8%) were AmpC b-lactamase isolates. For the 50
AmpC isolates, all phenotypic Amp C tests gave a positive result. Among these isolates, plasmid
encoded AmpC genes were detected by multiplex PCR in 46 (92%) isolates, which included
Klebsiella pneumoniae (n= 22) (47.8%), Escherichia coli (n= 15) (32.6%), and Proteus mirabilis
(n= 9) (19.6%). One E. coli, one K. pneumoniae, and two P. mirabilis isolates showed no AmpC
gene. The most prevalent AmpC gene was that belonging to family CMY-1 which was detected
in 73.9% (34/46) of all isolates.
Conclusion: It could be concluded that: Amp C producing isolates among Enterobacteriaceae
strains have been increasingly recognized in the Ain Shams University Hospital.
Thus, molecular identiﬁcation of the genes encoding AmpC would be essential for a reliable epi-
demiological investigation of their transmission in hospitals.
 2015 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prevalence of multidrug-resistant Gram-negative bacteria
has increased continuously over the past few years, and
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extended spectrum b-lactamases (ESBLs) are of particular
concern [14].
AmpC b-lactamases are clinically signiﬁcant because
they may confer resistance to penicillins, cephalosporins,
oxyimino-cephalosporins (e.g., ceftriaxone, cefotaxime, and
ceftazidime), cephamycins (e.g., cefoxitin and cefotetan), and
monobactams. AmpC b-lactamase activity is not affected by
the ESBL inhibitor clavulanic acid [25].
In the Ambler structural classiﬁcation of b-lactamases
AmpC enzymes belong to class C [3], while in the functional
classiﬁcation scheme of Bush et al., they were assigned to
group 1 [5].
Genes for AmpC b-lactamases are commonly found on the
chromosomes of several members of the family
Enterobacteriaceae, including Enterobacter, Shigella,
Providencia, Citrobacter freundii, Morganella morganii,
Serratia marcescens, and Escherichia coli [8].
In Gram-negative bacteria, AmpC b-lactamase production
is chromosome or plasmid mediated. Chromosomal AmpC
genes are expressed constitutively at a low level. Some
Enterobacteriaceae, such as Enterobacter species, Citrobacter
spp., and Serratia spp., carry an inducible AmpC gene. In
these cases, the gene is strongly induced by b-lactams, such
as cefoxitin and imipenem, with expression mediated by the
regulator AmpR. Mutations in the repressor gene AmpD
may lead to overproduction of AmpC b-lactamases [14].
Plasmid-based AmpC genes are expressed constitutively in
most cases. However, some plasmid-carried AmpC genes, such
as the DHA-1 gene, are inducible by b-lactams, with expression
regulated similar to that of inducible chromosomal AmpC
genes. All plasmid-carried AmpC genes are considered to be
of signiﬁcant clinical relevance [20]. AmpC overproduction in
addition to porin mutations of the outer membrane can reduce
susceptibility to carbapenems, in particular in plasmid-
mediated AmpC producers. Porins are chemically selective
and transport only one group of molecules, or may be speciﬁc
for one molecule. b-lactam and ﬂuoroquinolone antibiotics
must pass through porins to reach their targets in gram negative
bacteria. Bacteria can develop resistance to these antibiotics by
mutating the gene that encodes the porin – the antibiotics are
then excluded from passing through the outer membrane [17].
Although reported with increasing frequency in case iso-
lates, the true rate of occurrence of plasmid mediated AmpC
b-lactamases in Klebsiella pneumoniae, E. coli, and Proteus mir-
abilis remains unknown. Many laboratories have difﬁculty in
detecting these enzymes in clinical isolates [8].
There are no Clinical Laboratory Standards Institute
(CLSI) or other approved criteria for AmpC detection.
Organisms producing enough AmpC b-lactamase will typically
give a positive ESBL screening test but fail in the conﬁrmatory
tests involving increased sensitivity with clavulanic acid [22].
This phenotype is not, however, speciﬁc for an AmpC pro-
ducer, since it can occur with certain complex TEM mutants,
OXA-type ESBLs, and carbapenemases and in strains with
high levels of TEM-1 b-lactamase. Other conﬁrmatory tests
are needed [9].
This study aimed to evaluate the presence of AmpC
b-lactamase among Enterobacteriaceae isolates separated from
patients with nosocomial infections, and to detect the genetic
basis for AmpC production in these strains.2. Material and methods
This study was conducted on 50 AmpC b-lactamase
Enterobacteriaceae isolates (23 K. pneumoniae, 16 E. coli, 11
P. mirabilis) in the Medical Microbiology and Immunology
department of the Ain Shams University from a total of 148
Enterobacteriaceae clinical isolates, from intensive care unit
(ICU) admitted patients attending the department of surgery
of the Ain Shams University Hospital. Samples were collected
in the period from May to October 2014. These isolates were
obtained from various clinical specimens (55 respiratory
specimens of sputum and endotracheal aspirate (ETA), 39
pus specimens from cases of open wounds or open abscesses
using a sterile swab, and 29 mid-stream urine (MSU) taken
from non catheterized patients and catheter-stream urine
(CSU) in catheterized patients taken from the catheter tube
using a sterile syringe, and 25 blood samples for blood cul-
ture). All samples were collected under aseptic conditions.
All isolates were cultured on Mac Conkey’s agar (Difco/BD
Diagnostics Systems, Sparks, MI, USA), blood agar media
(Oxoid Ltd., Basingstoke, UK), and Cysteine Lactose
Electrolytes Deﬁcient (CLED) agar using 1 ll calibrated loop
to detect colony forming unit (CFU) per milliliter (for urine
specimens) and then incubated aerobically at 37 C for 24 h.
All isolated Enterobacteriaceae were worked up microbiologi-
cally and identiﬁed by conventional microbiological methods
(colonial morphology, Gram staining, and biochemical tests)
according to Cheesebrough [6].
Antibiotic susceptibility testing was performed using
susceptibility test disks (Becton Dickinson, Germany), and
interpretation was done according to 2013 CLSI guidelines
[7]. Susceptibility testing was performed on Mueller–Hinton
agar (bioMe´rieux, France), using overnight cultures at a 0.5
McFarland standard followed by incubation at 35 C for
16–18 h.
2.1. AmpC screening using the disk diffusion method
Cefoxitin resistance strains were detected using cefoxitin disk
30-ug (Becton Dickinson). Isolates with zone diameters less
than 18 mm were considered AmpC positive and selected for
conﬁrmation of AmpC production.
The phenotypic AmpC conﬁrmatory tests were performed
on all isolates by the AmpC E test (AB bio-Me´rieux,
Sweden), the disk approximation test, and Amp C EDTA disc.
Then molecular detection of plasmid mediated AmpC by
multiplex PCR was conducted on the 50 AmpC b-lactamase
Enterobacteriaceae isolates.
2.2. Detection of AmpC b-lactamases
2.2.1. Phenotypic AmpC conﬁrmation methods
1. AmpC E testing: The AmpC E test (AB bio-Me´rieux,
Sweden) for cefotetan susceptibility was performed accord-
ing to the manufacturer’s instructions. The AmpC E test
consists of a strip containing cefotetan on one end and cefo-
tetan-cloxacillin on the other end. Ratios of the MICs of
cefotetan and cefotetan-cloxacillin of P8 are considered
positive for AmpC b-lactamase production.
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designed to detect AmpC production. A conventional disk
diffusion susceptibility assay is carried out with a suscepti-
ble strain, such as E. coli ATCC 25922. A 0.5 McFarland
bacterial suspension from an overnight blood agar plate,
Inoculate surface of the MHA plate. A 30 lg ceftazidime
disk was placed at the center of the plate then 10 lg imipe-
nem, 30 lg cefoxitin, and 20/10 lg amoxicillin/clavulanate
disks were placed at a distance of 20 mm from the ceftazi-
dime disk. The plate was inverted and incubated overnight
at 37 C. After overnight incubation, if there is any obvious
blunting or ﬂattening of the zone of inhibition between the
ceftazidime disk and the inducing substrates (imipenem,
cefoxitin and amoxicillin/clavulanate disk) it will be
considered as a positive result for AmpC production [12].
3. AmpC EDTA disk test. The test is based on the use of
Tris–EDTA to permeabilize a bacterial cell and release
b-lactamases into the external environment. AmpC disks
(i.e., ﬁlter paper disks containing Tris–EDTA) were pre-
pared by applying 20 ll of a 1:1 mixture of saline and
Tris–EDTA to sterile ﬁlter paper disks, allowing the disks
to dry, and storing them at 2 to 8 C. The surface of a
Mueller–Hinton agar plate (Oxoid Ltd., Basingstoke, and
Hampshire, England) was inoculated with a lawn of cefox-
itin- susceptible E. coli ATCC 25,922 according to the stan-
dard disk diffusion method [4]. Immediately prior to use,
AmpC disks were rehydrated with 20 ll of saline and sev-
eral colonies of each test organism were applied to a disk.
A 30 lg cefoxitin disk (Becton Dickinson, Sparks, MD)
was placed at the inoculated surface of the Mueller–
Hinton agar. The inoculated AmpC disk was then placed
almost touching the antibiotic disk with the inoculated disk
face in contact with the agar surface. The plate was then
inverted and incubated overnight at 35 C in ambient air.
After incubation, plates were examined for either an inden-
tation or a ﬂattening of the zone of inhibition, indicating
enzymatic inactivation of cefoxitin (positive result), or the
absence of a distortion, indicating no signiﬁcant inactiva-
tion of cefoxitin (negative result).
Molecular detection of plasmid mediated AmpC by
multiplex PCR was conducted on the 50 AmpC b-lactamase
Enterobacteriaceae isolates as follows:
2.2.2. Molecular detection of AmpC b-lactamase
2.2.2.1. Preparation of template DNA. A single colony of each
organism was inoculated from a blood agar plate into 5 ml of
broth and incubated for 20 h at 37 C with shaking. Cells from
1.5 ml of the overnight culture were harvested by centrifuga-
tion for 5 min. After the supernatant was decanted, the pellet
was resuspended in 500 ll of distilled water. The cells were
lysed by heating at 95 C for 10 min, and cellular debris was
removed by centrifugation for 5 min. The supernatant, 2 ll
(1/250 volume) of the total sample, was used as the source of
template for ampliﬁcation.
2.2.2.2. Protocol for multiplex. Multiplex PCR was performed
for ampliﬁcation of genes for the most common types of plas-
mid mediated AmpC b lactamases using the method described
by Pe´rez-Pe´rez and Hanson [21]. PCR was performed in a
DNA thermal cycler (Biometra, Germany) with a ﬁnal volumeof 50 ll in 0.5-ml thin-walled tubes. For the detection of
CMY-1 gene 5-GCT GCT CAA GGA GCA CAG GAT-3
was used as forward primer (corresponding to nucleotides
358–378) and CAC ATT GAC ATA GGT GTG GTG
C-3 was used as the reverse primer (corresponding to nucleo-
tides 877–856) expected amplicon size 520 bp. For CMY-2
gene 5-TGG CCA GAA CTG ACA GGC AAA-3 was used
as a forward primer (corresponding to nucleotides 478–498)
and 5-TTT TC CTG AAC GTG GCT GGC-3 was used as a
reverse primer (corresponding to nucleotides 939–919)
expected amplicon size 462 bp. For ACC-1 gene 5-AAC
AGC CTC AGC AGC CGG TTA-3 (corresponding to
nucleotides 861–881) and 5-TTC GCC GCA ATC ATC
CCT AGC-3 was used as a reverse primer (corresponding to
nucleotides 1206–1186) expected amplicon size 346 bp. For
FOX-1 gene 5-AAC ATG GGG TAT CAG GGA GAT G-3
was used as a forward primer (corresponding to nucleotides
1475–11496) and 5-CAA AGC GCG TAA CCG GAT
TGG-3 was used as a reverse primer (corresponding to nucleo-
tides 1664–1644) expected amplicon size 190 bp [21].
PCR was performed with a ﬁnal volume of 50 ll in 0.5-ml
thin-walled tubes. Each reaction contained 20 mM Tris–HCl
(pH 8.4); 50 mM KCl; 0.2 mM each deoxynucleoside tripho-
sphate; 1.5 mM MgCl2; 0.6 lM primers and 1.25 U of Taq
DNA polymerase (Life Technologies, Rockville, MD).
Template DNA (2 ll) was added to 48 ll of the master mix-
ture and then overlaid with mineral oil. The PCR program
consisted of an initial denaturation step at 94 C for 3 min, fol-
lowed by 25 cycles of DNA denaturation at 94 C for 30 s, pri-
mer annealing at 64 C for 30 s, and primer extension at 72 C
for 1 min. After the last cycle, a ﬁnal extension step at 72 C
for 7 min was added. Five-microliter aliquots of PCR product
were analyzed by gel electrophoresis with 2% agarose (Bio-
Rad, Hercules, and Calif.). Gels were stained with ethidium
bromide at 10 lg/ml and visualized by UV transillumination.
A 100-bp DNA ladder from Life Technologies was used as a
marker. Negative controls were PCR mixtures with the addi-
tion of water in place of template DNA.
Ideally, all the primer pairs in a multiplex PCR should
enable similar ampliﬁcation efﬁciencies for their respective tar-
get. This may be achieved through the utilization of primers
with nearly identical optimum annealing temperatures (primer
length of 18–30 bp or more and a GC content of 35–60% may
prove satisfactory) and should not display signiﬁcant homol-
ogy either internally or to one another.
2.3. Statistical methods
Data were coded and entered using the statistical package SPSS
version 15. Data were summarized using descriptive statistics:
number and percentage for qualitative values. Statistical differ-
ences between independent groups were tested using the Chi
Square test for qualitative variables while dependent group
comparisons were done using Cochrane and MacNemar tests.3. Results
From a total of 148 Enterobacteriaceae isolates [85 (57.4%) K.
pneumoniae, 42 (28.4%) E. coli, and 21 (14.2%) P. mirabilis],
that were obtained from 148 clinical samples from ICU
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(37.2%) from sputum, 39 (26.3%) from pus aspirates, 29
(19.6%) from urine, and 25 (16.9%) from blood].
All isolates were screened for cefoxitin resistance strains
using cefoxitin disk 30-ug. AmpC positive strains were selected
for conﬁrmation of AmpC b-lactamase phenotypically by
AmpC E test (AB bio-Me´rieux, Sweden), the disk approx-
imation test, and Amp C EDTA disc.
From the 148 total isolates, 50 (33.8%) were AmpC b-lac-
tamase isolates [23/50 (46%) K. pneumoniae, 16/50 (32%)
E. coli, 11/50 (22%) P. mirabilis], that were obtained from
clinical isolates as follows: 20/55 (36.4%) from sputum, 12/
39 (30.8%) from pus aspirates, 9/29 (31%) from urine, and
9/25 (36%) from blood (Table 1). For 50/148 (33.8%)
AmpC isolates, all phenotypic AmpC tests gave a positive
result for AmpC production.
Molecular detection of plasmid mediated AmpC by multi-
plex PCR was conducted on the 50 AmpC b-lactamase
isolates.
Among the 50 AmpC b-lactamase isolates, plasmid
encoded AmpC genes were detected by multiplex PCR in 46
(92%) isolates, which included K. pneumoniae (n= 22)
(47.8%), E. coli (n= 15) (32.6%), and P. mirabilis (n= 9)
(19.6%). One E. coli, one K. pneumoniae, and two P. mirabilis
isolates showed no AmpC gene (Table 2).
The most prevalent AmpC gene was that belonging to fam-
ily CMY-1 which was detected in 73.9% (34/46).
Genotyping of PCR products from ampliﬁcation of plas-
mid AmpC genes showed that the CMY genes from 15 K.
pneumoniae isolates, 12 E. coli isolates, and 7 P. mirabilis iso-
lates were homologs to CMY-1 gene. CMY-2 genes were
detected in 12 K. pneumoniae, 9 E. coli, and 5 P. mirabilis
isolates.
Genotyping for PCR product showed that FOX-1 genes
were detected in 9 K. pneumoniae, 5 E. coli, and were not
detected in P. mirabilis isolates. No genes belonging to the
ACC-1 were detected in all isolates. Gene belonging to CMY
family was the only one found in P. mirabilis.
There were 74 AmpC genes detected in the 92% (46/50) of
the positive phenotypic screened isolates. MOX group genes
(including CYM-1) were the predominant type in all isolatesTable 1 AmpC b-lactamase Enterobacteriaceae isolates.
Isolates Total no. AmpC positive isolates %
Klebsiella pneumonia 85 23 27.1
E. coli 42 16 38.1
Proteus mirabilis 21 11 52.4
148 50 33.8
Table 2 Distribution of ampC genes (CMY-1 and 2, FOX-1 and A
Organism No. (%) of isolates
AmpC genes positive CMY positive
CMY-1 CMY-2
Klebsiella pneumoniae 22 (47.8%) 15 (68.2%) 12 (54.
E. coli 15 (32.6%) 12 (80%) 9 (60%
Proteus mirabilis 9 (19.6%) 7 (77.8%) 5 (55.6(n= 34/46, 73.9%) followed by CIT group genes (including
CMY-2) (n= 26/46, 56.5%) then FOX group genes (include
FOX-1) (n= 14/46, 30.4%).
CMY genes were predominantly present in E. coli (CMY-1,
n= 12/15, 80%) (CMY-2, n= 9/15, 60%) and P. mirabilis
(CMY-1, n= 7/9, 77.8%) (CMY-2, n= 5/9, 55.6%), but were
also found in Klebsiella spp. (CMY-1, n= 15/22, 68.2%)
(CMY-12, n= 12/22, 54.5%). FOX-1 genes were present pre-
dominantly in the Klebsiella spp. (n = 9/22, 40.9%) but also
found in E. coli isolates (n = 5/15, 33.3%), and not found in
P. mirabilis.
In some of these isolates there were more than one gene
detected. As regards K. pneumoniae, ﬁve isolates have both
CMY-1 and CMY-2, 7 isolates have both CMY-1 and FOX-
1 and 2 isolates have the three genes CMY-1, CMY-2 and
FOX-1. For E. coli 6 isolates have both CMY-1 and CMY-
2, 3 isolates have CMY-1, FOX-1 and 2 isolates have the three
genes CMY-1, CMY-2 and FOX-1. For P. mirabilis 3 isolates
have both CMY-1 and CMY-2 (see Fig. 1).
4. Discussion
Drug resistance poses a therapeutic problem not only in the
hospital settings, but also in the community as most of the bac-
teria have acquired resistance to multiple antibiotics. The vari-
ous mechanisms of drug resistance in Gram negative bacteria
include extended spectrum b-lactamases (ESBL) production,
AmpC b-lactamase production, efﬂux mechanism and porin
deﬁciency. In the clinical laboratory settings, the commonly
detected enzymes causing resistance are AmpC b-lactamases
and ESBLs. Clinical relevance of AmpC b-lactamases lies in
the fact that they confer resistance to both narrow and broad
spectrum cephalosporins, b-lactam/b-lactamase inhibitor
combinations and aztreonam [10].
Detection of AmpC is important to improve the clinical
management of patients suffering from infections and would
also provide us with sound epidemiological data. However,
there are no clinical and laboratory standard institute
guidelines for detection of AmpC mediated resistance in gram
negative clinical isolates and hence, it usually poses a problem
due to misleading results, especially so in phenotypic tests [13].
In this study, the prevalence of Amp-C producing strains
with multiplex PCR from the 50 isolates that were detected
as Amp-C positive by phenotypic methods were 92% (46/50)
from which 44% (22/50) in the Klebsiella spp., 30% (15/50)
in E. coli and 18% (9/50) in P. mirabilis. This rate of preva-
lence was much higher than the result of Wassef et al. [26],
who reported that 26.9% harbored the plasmid mediated
AmpC gene and that of Yilmaz et al. [29], who reported that
AmpC-producing strains were 10.9% (21/191) in E. coli andCC-1) within study isolates.
FOX-1 positive ACC-1 positive AmpC genes negative
5%) 9 (40.9%) 0 (0) 1 (4.5%)
) 5 (33.3%) 0 (0) 1 (6.7%)
%) 0 (0) 0 (0) 2 (22.2%)
have both CMY-1 and CMY-2.
CMY-1
CMY-2
FOX-1
Figure 1 Agarose gel electrophoresis of AmpC b-lactamase genes ampliﬁed from nine different isolates. Lane M is 100 bp DNA
markers. Lanes 1, 2 and 3 show ampliﬁed product of one Amp-C gene. Lanes 4, 5, 6 and 8 gene show ampliﬁed products of two Amp-C
genes. Lane 7 shows ampliﬁed product of one Amp-C gene. While in lane 9 there is no ampliﬁed product for any of Amp-C genes.
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The great difference in the results of these two studies was
because in this study the prevalence was calculated from the
50 isolates that were detected as Amp-C positive by phenotypic
methods while in the study of Yilmaz et al. [29], it was
calculated from whole isolates. Further population-based
prevalence studies are required to observe the true spread of
AmpC b-lactamases.
In this study, there were 74 Amp-C genes detected in the
92% of the positive phenotypic screened isolates. MOX group
genes (including CYM-1) were the predominant type in all iso-
lates (73.9%) followed by CIT group genes (including CMY-2)
(56.5%) then FOX group genes (include FOX-1) (30.4%) com-
pared to the result of Fam et al. [11], who reported that, in
clinical isolates of Enterobacteriaceae from Cairo, Egypt
Amp-C genes were detected in 28.3% of the study population
including E. coli, Klebsiella and P. mirabilis. CMY-2 enzyme
was found disseminating in all 6 AmpC-positive E. coli and
in 6/10 of Klebsiella species. Only one K. pneumoniae isolate
harbored CMY-4 while DHA-1 was detected in 3 Klebsiella
and in one P. mirabilis isolate. On the other hand the result
of Montgomery et al. [19], who reported that 22 AmpC genes
were detected in 25.8% of the positive cefoxitin screened
isolates of which 40.9% belonged to each of the MOX
and the FOX families, 13.6% belonged to the EBC family,
and 4.5% belonged to the CIT family.
In this study, both CMY-1 and CMY-2 were the most com-
mon genes detected in our region while the study of Fam et al.
[11], reported that CMY-2 and DHA-1 were the most common
gene clusters of AmpC in our region while other studies
reported that DHA-type enzymes have been previously
identiﬁed in Taiwan [24]and in China [28]. In Korea DHA-,
CMY/MOX-, and ACT-1/MIR-1-type enzymes have also been
identiﬁed [16].While in the United States, in addition to the
types mentioned above, DHA-, ACT-1/MIR-1, and FOX-type
enzymes have been identiﬁed [23]. In Japan, MOX-1, CMY-9,
CMY-19, CFE-1, CMY-2 and DHA-1 have been found in
clinical isolates [18]. Enzyme type CMY-2 is widely distributed
geographically. It has been reported in Algeria, France,Germany, Greece, India, Pakistan, Taiwan, Turkey, United
Kingdom and the United States. Several studies for the detec-
tion of AmpC b-lactamase producers in many countries (Saudi
Arabia, Taiwan, Korea, North and South America) revealed
geographical discrepancy in AmpC b-lactamase types [27].
In our study, CMY genes were predominantly present in
E. coli (CMY-1, 80%) (CMY-2, 60%) and P. mirabilis
(CMY-1, 77.8%) (CMY-2, 55.6%), but were also found in
the Klebsiella spp. (CMY-1, 68.2%) (CMY-12, 54.5%).
FOX-1 genes were present predominantly in Klebsiella spp.
(40.9%) but also found in E. coli isolates (33.3%), and not
found in P. mirabilis however there were detected in another
study by Al-Agamy [2]who detected CMY-2 in one K. pneumo-
niae isolate while other genes were not detected. In another
study, CMY-2 has been described in Salmonella enterica
serovar Typhimurium [1]. However, Ktari et al. [15], reported
detection of CMY-4 AmpC b-lactamase in K. pneumoniae
isolate in a Tunisian university hospital.
In our study, in some of these isolates, there is more than
one gene. As regards K. pneumoniae, ﬁve isolates have both
CMY-1 and CMY-2, 7 isolates have both CMY-1 and
FOX-1 and 2 isolates have the three genes CMY-1, CMY-2
and FOX-1. For E. coli 6 isolates have both CMY-1 and
CMY-2, 3 isolates have CMY-1, FOX-1 and 2 isolates have
the three genes CMY-1, CMY-2 and FOX-1. For P. mirabilis
3 isolates have both CMY-1 and CMY-2 Wassef et al. [26],
also reported one isolate (Klebsiella) harbored 3 genes
(blaFOX, blaMOX and blaCIT).
5. Conclusions
The gold standard for the detection of AmpC activity was
taken to be a combination of the phenotypic and genotypic
testing results. Since clinical laboratories are ﬁrst to encounter
bacteria with new forms of antibiotic resistance, they need
appropriate tools to recognize these bacteria, including trained
staff with sufﬁcient time and equipment to follow up impor-
tant observations. Because bacterial pathogens are constantly
changing, training must be an ongoing process. The methods
244 S.A. El-Hady, L.A. Adeland training that were previously adequate may no longer be
sufﬁcient against the newer types of pathogens.
Identiﬁcation of types of AmpC may aid in hospital infec-
tion control and help the physician to prescribe the most
appropriate antibiotic, thus decreasing the selective pressure,
which generates antibiotic resistance. Sequencing and typing
the strains may be required to better understand the genetic
relatedness and the molecular epidemiology of this resistance
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